Brought to you by 
Cancer Genetics nets $6.4mm through its IPO
30 Apr 2013
Executive Summary
After a series of postponements and amendments, diagnostics firm Cancer Genetics Inc. has finally completed its initial public offering, netting $6.4mm through the sale of 690k common shares (including the overallotment) at $10. The company initially filed in December 2011, and at different points over the 16 months had set intended ranges for the offering of anywhere from $6-13 per share, with hopes of selling between 600k and 5mm shares.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
Laboratory Testing Services
- Esoteric Laboratories
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cancer Genetics nets $6.4mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice